Premium
Advancing drug discovery for schizophrenia
Author(s) -
Marder Stephen R.,
Roth Bryan,
Sullivan Patrick F.,
Scolnick Edward M.,
Nestler Eric J.,
Geyer Mark A.,
Welnberger Daniel R.,
Karayiorgou Maria,
Guidotti Alessandro,
Gingrich Jay,
Akbarian Schahram,
Buchanan Robert W.,
Lieberman Jeffrey A.,
Conn P. Jeffrey,
Haggarty Stephen J.,
Law Amanda J.,
Campbell Brian,
Krystal John H.,
Moghaddam Bita,
Saw Akira,
Caron Marc G.,
George Susan R.,
Allen John A.,
Solis Michelle
Publication year - 2011
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1111/j.1749-6632.2011.06216.x
Subject(s) - vanguard , schizophrenia (object oriented programming) , foundation (evidence) , drug discovery , schizophrenia research , engineering ethics , medicine , psychiatry , political science , biology , bioinformatics , engineering , geography , archaeology , law
Sponsored by the New York Academy of Sciences and with support from the National Institute of Mental Health, the Life Technologies Foundation, and the Josiah Macy Jr. Foundation, “Advancing Drug Discovery for Schizophrenia” was held March 9–11 at the New York Academy of Sciences in New York City. The meeting, comprising individual talks and panel discussions, highlighted basic, clinical, and translational research approaches, all of which contribute to the overarching goal of enhancing the pharmaceutical armamentarium for treating schizophrenia. This report surveys work by the vanguard of schizophrenia research in such topics as genetic and epigenetic approaches; small molecule therapeutics; and the relationships between target genes, neuronal function, and symptoms of schizophrenia.